Tags : Therapeutic

Roche Licenses Halozyme’s ENHANZE Technology for ~$190M for the Development

Vartika Singh October 31, 2018

Shots: Halozyme to receive $25M upfront plus $160 to $165M/target milestones payments based on development, regulatory & sales in addition to royalties. Roche to get rights for ENHANZE Technology for […]readmore

M&A

Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Vartika Singh October 10, 2018

Shots: Therachon gains exclusive commercialization and development rights to apraglutide, initially developed by Ferring Pharma and was exclusively licensed by GLyPharma in 2012. Novo Holdings to fund the transaction with […]readmore

Tags : Therapeutic

Roche Licenses Halozyme’s ENHANZE Technology for ~$190M for the Development

Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Therapeutic

Roche Licenses Halozyme’s ENHANZE Technology for ~$190M for the Development

Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company